Other languages Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Real-time Estimate Cboe BZX Other stock markets 10:35:52 2024-04-26 am EDT			5-day change	1st Jan Change
21.52 ^USD	-0.35%		-10.25%	-21.20%

Apr. 04	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
Apr. 04	Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	Mar. 26
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	Mar. 26
Beam Therapeutics Shares Jump on Surprise Q4 Profit	Feb. 27
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	Feb. 27
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	Jan. 30
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	Jan. 29
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	Jan. 08
Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors	Dec. 14
Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	23-10-31
Eli Lilly to Acquire Beam Therapeutics' Opt-In Rights to Verve Therapeutics' Cardiovascular Programs	23-10-31
Eli Lilly and Company Agree to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease	23-10-31
Sector Update: Health Care	23-10-19
Beam Therapeutics to Cut 20% of Workforce to Reduce Costs; Shares Fall	23-10-19
Beam, Inc. Announces Plans to Advance Clinical Trials and Programs	23-10-19
Beam Therapeutics Inc. Presents Preclinical Data Highlighting Utility of Beam-302 to Correct an Alpha-1 Antitrypsin Deficiency Disease-Causing Mutation	23-09-07
Sector Update: Health Care Stocks Steady Premarket Tuesday	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST